NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Categories: STAT

7 9/26/2018

STAT’s cheerleading coverage of prescription fish oil capsule lacks crucial context


STAT suggests flu drug could ‘upend treatment,’ but there’s plenty to question about this claim


Small ‘diabetes vaccine’ study: STAT provides lots of useful numbers for readers


Antibiotics could ‘dramatically reduce’ STIs, STAT says, though findings apply to small group of men


STAT provides readers with necessary details to make sense of new PSA screening study


STAT puts $950 DNA-based fertility test under the microscope


Vaccine shows protection against gonorrhea, STAT reports. But what about the costs and potential harms?


STAT’s cautious story provides interesting insights into challenges of Alzheimer’s research


Facial-recognition software for diagnosing genetic disorders: STAT leaves too many questions unanswered


Vitamins delivered via IV: STAT wisely asks ‘where’s the evidence?’